FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to pulmonology and infectious diseases, and is intended for treating pulmonary disease in a subject. For the treatment of pulmonary disease in a subject, a stable pharmaceutical aqueous composition for inhalations containing 0.1 mg/ml to 100 mg/ml of a hexapeptide of formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof is used. Composition has pH from 3.0 to 8.5. Method of treating pulmonary disease in a subject in need thereof involves administering to said subject a therapeutically effective amount of said stable pharmaceutical aqueous composition for inhalations.
EFFECT: use of the group of inventions provides targeted delivery of the active substance into the lungs and multiple increases therapeutic levels of the hexapeptide (I) in the lungs compared to those achieved by injecting the hexapeptide in the same dose.
7 cl, 8 tbl, 10 ex, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
USE OF DALARGIN FOR PRODUCTION OF DRUG PREPARATIONS FOR PREVENTING PNEUMONIA | 2020 |
|
RU2728938C1 |
MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
MEANS AND METHOD FOR PREVENTION OF INTERSTITIAL PNEUMONIA OF INFECTIOUS ETIOLOGY | 2021 |
|
RU2784177C1 |
METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2781968C1 |
SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUPPOSITORY CONTAINING HEXAPEPTIDE | 2020 |
|
RU2737800C1 |
AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
Authors
Dates
2020-12-25—Published
2020-05-29—Filed